This is a proof-of-concept study in 2 parts. In Part A, patients will receive OBE022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between 28 0/7 and 33 6/7 weeks. Part B has a double-blind, randomised, placebo controlled, parallel group and multicentre design and will assess the efficacy, safety and pharmacokinetics in pregnant women with threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks. All patients in part A and part B must receive atosiban infusion for 48 hours as standard of care treatment. Patients from Part A will receive OBE022 open label. Patients from Part B will be randomised to receive OBE022 or matching placebo. IMP treatment duration will be up to 7 days. IMP treatment will be stopped in case of delivery prior to Day 7.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
115
Oral
Oral
I.V.
Gynekologicko-porodnická klinika Fakultní nemocnice Brno
Brno, Czechia
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
Prague, Czechia
Ústav pro péči o matku a dítě
Prague, Czechia
Helsinki Universisty Hospital
Helsinki, Finland
Hilel Yafe Medical Center, Maternal Fetal Unit
Haifa, Israel
Rambam Medical Center, Maternal Fetal Unit
Haifa, Israel
Meir Medical Center, Obstetrics and Gynecology Department
Kfar Saba, Israel
Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women
Petah Tikva, Israel
Moscow Regional Perinatal Center
Balashikha, Russia
Kazan State Medical University
Kazan', Russia
...and 8 more locations
Incidence of delivery within 2 days (48 h) from start of IMP administration
Time frame: 48 hours
Incidence of delivery within 7 days (168 h) from start of IMP administration
Time frame: 168 hours
Incidence of delivery before 37 weeks of GA
Time frame: Up to 13 weeks from start of IMP administration
Time to delivery measured from start of IMP administration
Time frame: Up to 17 weeks from start of IMP administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.